Yesterday, Alfen published FY24 revenues (down 3.3% YoY at EUR487.6m) broadly in line with consensus and BGe expectations (respectively EUR483.0m and EUR485.2m). Gross margin, however, came in at 23.7% (-6.3ppt vs. 30.0% in FY23) and was affected by significant one-off items whereas adjusted EBITDA
Below are the highlights from the 4Q24 results conference call. 4Q adj EBITDA jumped by 37% and was about 2% better than our and consensus forecasts. Dsm-firmenich guides for at least 13% adj. EBITDA growth in FY25, on the back of a combination of synergies, savings and continued benefit from temporary high vitamin prices. The company is still looking to exit the ANH business and, reflecting the strong balance sheet, has announced a € 1bn share buyback program. We still appreciate dsm-firmenich ...
Ackermans & van Haaren: Acquisition of boutique wealth manager Petram & Co. Alfen: Takes care of costs and debt, guidance misses. Arcadis: Solid backlog growth provides comfort. BAM: A friend of ours, 10% yield. CM.com: 2H24 results – FCF positive, capital restructuring. dsm-firmenich: Cash in, cash back. Flow Traders: Roller Coaster. KBC: Encouraging outlook to 2027, poor dividend. RELX: FY24 results – in line, £1.5bn buyback in 2025. Talabat: A beat at its maiden 4Q24 results...
FY24 net revs grew 4.5% org. to €3880m (vs. our €3901m and css of €3914m). Operating EBITA landed at €447m (vs. our €435m and css of € 443m) discounting an 11.5% margin up from 10.4% in FY23. The backlog rose to €3673m up 16.3% organically y/y. 4Q order intake of €998m was particularly strong in Resilience & Places with overall book-to-bill ratio of 1.04x down from 1.3x in 3Q24. However the latter quarter experienced exceptional order intake in Mobility. A €1 dps (€0.95 est.) is proposed.
Enter Private Bank has reached an agreement to acquire 100% of Petram & Co., an asset manager based in Utrecht, Netherlands. This is Delen's 6th acquisition (over the last 9 years) in the Netherlands since it entered the Dutch market in 2016 with the acquisition of Oyens & Van Eeghen. While we do welcome the news of Delen's growth, we are not entirely surprised. AvH management, over the last 2 years, has already mentioned that for the Private Banking Division, the Netherlands offers sufficient o...
Galapagos reported FY24 results which came with a pipeline prioritisation providing clarity on the path to market lead program GLPG5101 (CD19 CAR-T). With pivotal development planned for 2026 in 8 B-cell malignancies and a first approval targeted for 2028, Galapagos' CAR-T plans are shaping up. YE24 cash came in at € 3.3b and Galapagos will have 500m following the business split announced in January, sufficient to fund the company to reach its next inflection milestones and we expect renewed int...
4Q adj EBITDA jumped by 37% and was about 2% better than our and consensus forecasts. Dsm-firmenich guides for at least 13% adj. EBITDA growth in FY25, on the back of a combination of synergies, savings and continued benefit from temporary high vitamin prices. The company is still looking to exit the ANH business and, reflecting the strong balance sheet, has announced a € 1bn share buyback program. We still appreciate dsm-firmenich for its broad portfolio and market leading positions. The upcomi...
Arcadis Q4 and Full Year 2024 Results: Record earnings per share, record backlog, enhanced long term visibility PRESS RELEASE | Arcadis Fourth Quarter and Full Year Results 2024 Record earnings per share, record backlog, enhanced long term visibility FOURTH QUARTER Strong Order Intake of €1.0 billion resulting in Book to Bill of 1.04xRecord fourth quarter operating EBITA margin of 12.6% (Q4‘23: 11.4%)Free Cash Flow generation of €183 million (Q4‘23: €208 million)Bolt-on acquisition of Data Center Design business in Germany FULL YEAR Record backlog of €3.7 billion, organic growt...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.